Overview

A FULLY INTEGRATED BIOPHARMACEUTICAL COMPANY WITH A ROBUST PIPELINE ACROSS MULTIPLE THERAPEUTIC AREAS INCLUDING ONCOLOGY, OPHTHALMOLOGY, AND IMMUNOLOGY.

Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated through net sales of its diversified portfolio of FDA-approved therapeutics.

The foundational therapy in our immuno-oncology pipeline is LOQTORZI, a next-generation PD-1 inhibitor. Through our acquisition of Surface Oncology, Coherus’ immuno-oncology pipeline includes casdozokitug, a novel first-in-class anti-IL-27 antibody currently being evaluated in Phase 1/2 clinical trials in lung and liver cancer. CHS-114 is a highly selective, competitively positioned anti-CCR8 antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors.

Coherus’ earlier-stage immuno-oncology pipeline includes CHS-006, a TIGIT-targeted antibody, being evaluated in combination with toripalimab, CHS-1000, a proprietary ILT4 antibody, and other immuno-therapies targeting novel pathways.

Coherus markets UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta®, CIMERLI® (ranibizumab-eqrn), a biosimilar of Lucentis®, YUSIMRY™ (adalimumab-aqvh) a biosimilar of Humira® and plans to launch LOQTORZI™ (toripalimab-tpzi), next-generation PD-1 inhibitor, in Q1 2024.

Coherus is headquartered in the heart of California’s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.

12/07/23	Coherus BioSciences Announces CFO Transition Plans REDWOOD CITY, Calif. , Dec. 07, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that McDavid Stilwell, Chief Financial Officer (CFO), has resigned from the company to pursue other opportunities. Mr. Stilwell’s last day of employment with Coherus will
12/06/23	Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress – Casdozokitug has demonstrated anti-tumor activity alone and in combination with an anti-PD-1 antibody; two of nine squamous NSCLC patients had confirmed partial responses – – Data support continued evaluation of casdozokitug in combination with anti-PD-1 antibody treatments including ongoing
11/28/23	Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association – Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with LOQTORZI plus chemotherapy significantly prolongs survival in patients with recurrent or metastatic NPC irrespective of PDL-1 status– – Treatment resulted in a 37% reduction in the risk of death versus
11/06/23	Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights – Net revenue rose 27% from prior quarter to $74.6 million – – CIMERLI ® net sales increased 50% to $40 million compared to prior quarter – – LOQTORZI ™ now approved with launch planned for the first quarter of 2024 – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif. , Nov.

View All